CO6210734A2 - Conjugados de anticuerpo anti-rg-1 - Google Patents
Conjugados de anticuerpo anti-rg-1Info
- Publication number
- CO6210734A2 CO6210734A2 CO10064681A CO10064681A CO6210734A2 CO 6210734 A2 CO6210734 A2 CO 6210734A2 CO 10064681 A CO10064681 A CO 10064681A CO 10064681 A CO10064681 A CO 10064681A CO 6210734 A2 CO6210734 A2 CO 6210734A2
- Authority
- CO
- Colombia
- Prior art keywords
- seq
- chain variable
- variable region
- antibody
- heavy chain
- Prior art date
Links
- 229940127121 immunoconjugate Drugs 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 1
- 239000002619 cytotoxin Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99169007P | 2007-11-30 | 2007-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6210734A2 true CO6210734A2 (es) | 2010-10-20 |
Family
ID=40427118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10064681A CO6210734A2 (es) | 2007-11-30 | 2010-05-28 | Conjugados de anticuerpo anti-rg-1 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20110020329A1 (enExample) |
| EP (1) | EP2211908A2 (enExample) |
| JP (1) | JP2011505371A (enExample) |
| KR (1) | KR20100101122A (enExample) |
| CN (1) | CN101951960A (enExample) |
| AR (1) | AR069746A1 (enExample) |
| AU (1) | AU2008331507A1 (enExample) |
| BR (1) | BRPI0819765A2 (enExample) |
| CA (1) | CA2707443A1 (enExample) |
| CL (1) | CL2008003525A1 (enExample) |
| CO (1) | CO6210734A2 (enExample) |
| EA (1) | EA201000921A1 (enExample) |
| IL (1) | IL206060A0 (enExample) |
| MX (1) | MX2010005683A (enExample) |
| NZ (1) | NZ586514A (enExample) |
| TW (1) | TW200930407A (enExample) |
| WO (1) | WO2009073524A2 (enExample) |
| ZA (1) | ZA201003729B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5014988B2 (ja) * | 2004-07-16 | 2012-08-29 | マイクロメット アクツィエン ゲゼルシャフト | 発現増強ポリペプチド |
| HUE035798T2 (en) | 2008-11-03 | 2018-05-28 | Syntarga Bv | CC-1065 analogues and conjugates |
| NO3056203T3 (enExample) | 2010-04-21 | 2018-05-12 | ||
| IL299365A (en) | 2010-05-27 | 2023-02-01 | Genmab As | Monoclonal antibodies against 2HER |
| NZ604007A (en) * | 2010-05-27 | 2015-03-27 | Genmab As | Monoclonal antibodies against her2 epitope |
| US8852599B2 (en) | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
| TR201810856T4 (tr) | 2014-01-10 | 2018-08-27 | Synthon Biopharmaceuticals Bv | CYS'le bağlı antikor-ilaç konjugatlarını saflaştırmak için usul. |
| CA2937561A1 (en) * | 2014-01-29 | 2015-08-06 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Ligand-cytotoxic drug conjugate, preparation method thereof, and uses thereof |
| SG11202000820PA (en) * | 2017-07-31 | 2020-02-27 | Tizona Therapeutics | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4912227A (en) * | 1984-02-21 | 1990-03-27 | The Upjohn Company | 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds |
| US4978757A (en) * | 1984-02-21 | 1990-12-18 | The Upjohn Company | 1,2,8,8a-tetrahydrocyclopropa (C) pyrrolo [3,2-e)]-indol-4(5H)-ones and related compounds |
| US5332837A (en) * | 1986-12-19 | 1994-07-26 | The Upjohn Company | CC-1065 analogs |
| US5084468A (en) * | 1988-08-11 | 1992-01-28 | Kyowa Hakko Kogyo Co., Ltd. | Dc-88a derivatives |
| JP2598116B2 (ja) * | 1988-12-28 | 1997-04-09 | 協和醗酵工業株式会社 | 新規物質ｄｃ１１３ |
| JP2510335B2 (ja) * | 1989-07-03 | 1996-06-26 | 協和醗酵工業株式会社 | Ｄｃ―８８ａ誘導体 |
| US5187186A (en) * | 1989-07-03 | 1993-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Pyrroloindole derivatives |
| AU648313B2 (en) * | 1990-04-25 | 1994-04-21 | Pharmacia & Upjohn Company | Novel CC-1065 analogs |
| US6214345B1 (en) * | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| DE69533277T2 (de) * | 1994-04-22 | 2005-07-21 | Kyowa Hakko Kogyo Co., Ltd. | Dc-89 derivat |
| JPH07309761A (ja) * | 1994-05-20 | 1995-11-28 | Kyowa Hakko Kogyo Co Ltd | デュオカルマイシン誘導体の安定化法 |
| US5871969A (en) * | 1996-02-12 | 1999-02-16 | Human Genome Sciences, Inc. | Nucleic acids encoding human neuronal attachment factor-1 |
| US6682902B2 (en) * | 1999-12-16 | 2004-01-27 | Schering Aktiengesellschaft | DNA encoding a novel RG1 polypeptide |
| KR20030033007A (ko) * | 2001-05-31 | 2003-04-26 | 코울터 파머수티컬, 인코포레이티드 | 세포독소, 약물전구체, 링커 및 이에 유용한 안정화제 |
| EP1423110A4 (en) * | 2001-09-07 | 2005-04-27 | Scripps Research Inst | CBI ANALOGUE OF CC-1065 AND DUOCARMYCINES |
| US7091186B2 (en) * | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| PE20050712A1 (es) * | 2003-07-22 | 2005-11-02 | Schering Ag | Anticuerpos rg1 |
| BRPI0510909A2 (pt) * | 2004-05-19 | 2008-12-16 | Medarex Inc | composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor |
| US7691962B2 (en) * | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
| US7714016B2 (en) * | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
| EA016577B1 (ru) * | 2005-09-26 | 2012-06-29 | Медарекс, Инк. | Конъюгаты антитело-лекарство и их применение |
| WO2007059404A2 (en) * | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
| EP2799449A1 (en) * | 2006-05-25 | 2014-11-05 | Bayer Intellectual Property GmbH | Dimeric molecular complexes |
-
2008
- 2008-11-26 JP JP2010536173A patent/JP2011505371A/ja not_active Withdrawn
- 2008-11-26 CL CL2008003525A patent/CL2008003525A1/es unknown
- 2008-11-26 BR BRPI0819765 patent/BRPI0819765A2/pt not_active IP Right Cessation
- 2008-11-26 MX MX2010005683A patent/MX2010005683A/es not_active Application Discontinuation
- 2008-11-26 CN CN2008801259196A patent/CN101951960A/zh active Pending
- 2008-11-26 AU AU2008331507A patent/AU2008331507A1/en not_active Abandoned
- 2008-11-26 WO PCT/US2008/084899 patent/WO2009073524A2/en not_active Ceased
- 2008-11-26 EP EP08858236A patent/EP2211908A2/en not_active Withdrawn
- 2008-11-26 CA CA2707443A patent/CA2707443A1/en not_active Abandoned
- 2008-11-26 AR ARP080105135A patent/AR069746A1/es not_active Application Discontinuation
- 2008-11-26 EA EA201000921A patent/EA201000921A1/ru unknown
- 2008-11-26 NZ NZ586514A patent/NZ586514A/en not_active IP Right Cessation
- 2008-11-26 TW TW097145816A patent/TW200930407A/zh unknown
- 2008-11-26 US US12/745,337 patent/US20110020329A1/en not_active Abandoned
- 2008-11-26 KR KR1020107014394A patent/KR20100101122A/ko not_active Withdrawn
-
2010
- 2010-05-25 ZA ZA2010/03729A patent/ZA201003729B/en unknown
- 2010-05-28 CO CO10064681A patent/CO6210734A2/es not_active Application Discontinuation
- 2010-05-30 IL IL206060A patent/IL206060A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008331507A1 (en) | 2009-06-11 |
| CA2707443A1 (en) | 2009-06-11 |
| AR069746A1 (es) | 2010-02-17 |
| TW200930407A (en) | 2009-07-16 |
| MX2010005683A (es) | 2010-06-11 |
| EA201000921A1 (ru) | 2010-12-30 |
| IL206060A0 (en) | 2010-11-30 |
| ZA201003729B (en) | 2011-08-31 |
| US20110020329A1 (en) | 2011-01-27 |
| EP2211908A2 (en) | 2010-08-04 |
| WO2009073524A2 (en) | 2009-06-11 |
| WO2009073524A3 (en) | 2009-12-10 |
| JP2011505371A (ja) | 2011-02-24 |
| CN101951960A (zh) | 2011-01-19 |
| KR20100101122A (ko) | 2010-09-16 |
| NZ586514A (en) | 2012-05-25 |
| BRPI0819765A2 (pt) | 2015-05-05 |
| CL2008003525A1 (es) | 2010-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR050642A1 (es) | Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/ calicheamicina | |
| AR064109A1 (es) | Anticuerpos humanos que se enlazan al cd22 y sus usos | |
| PE20121552A1 (es) | Anticuerpos monoclonales anti cea humanizados de afinidad madura | |
| WO2019215510A8 (en) | Compositions and methods related to anti-cd19 antibody drug conjugates | |
| AR069746A1 (es) | Conjugados de anticuerpos anti- rg-1 | |
| PH12020551689A1 (en) | Her2-targeting antigen binding molecules comprising 4-1bbl | |
| AR091605A1 (es) | Proteinas de union anti-mesotelina | |
| CO6290705A2 (es) | Anticuerpos monoclonales aislados o porciones de union a antigenos, que se unen especificamente a la integrina alfa 5-beta1, y composiciones farmaceuticamente aceptables de los mismos | |
| AR063090A1 (es) | Proteinas de union al antigeno del receptor de la il-17 | |
| EA201391159A1 (ru) | Hla-рестриктированные пептидоспецифические антигенсвязывающие белки | |
| PE20091196A1 (es) | Anticuerpos contra el vegf completamente humano, composiciones y metodos | |
| BR112018008983A2 (pt) | moléculas de ligação específicas para asct2 e seus usos | |
| WO2011159847A3 (en) | Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof | |
| NI200900005A (es) | Anticuerpo antagonista para el tratamiento del cáncer | |
| MX2022016180A (es) | Conjugados anticuerpo-fármaco que comprenden anticuerpos anti-b7-h3. | |
| PE20120549A1 (es) | Proteinas biespecificas de union a antigenos | |
| MX2010005830A (es) | Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo. | |
| CR10656A (es) | Proteinas de union a interleuquina-13 | |
| EA201001335A1 (ru) | Антитела, направленные против ангиопоэтина-1 и ангиопоэтина-2, и их применение | |
| PE20090368A1 (es) | Anticuerpos anti-igf | |
| PE20080035A1 (es) | Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina | |
| UA116874C2 (uk) | Імунокон'югат анти-мезотеліну | |
| ECSP12011761A (es) | Moléculas de anticuerpo anti-gcc y composiciones y métodos relacionados. | |
| AR073538A1 (es) | Anticuerpos multiespecificos que se unen especificamente al receptor del factor de crecimiento epidermico humano 2 (her2) y al factor de crecimiento endotelial vascular (vegf) | |
| BR112012023010A2 (pt) | "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |